97 citations
,
January 2020 in “Advances in chronic kidney disease” This review describes the toxicities associated with calcineurin inhibitors, used in kidney transplantation, which include nephrotoxicity, cardiovascular and endocrine issues, and quality of life impacts, without reporting new clinical results.
7 citations
,
August 2025 in “European Journal of Endocrinology” The authors concluded that incorporating routine endocrinology consultations into transplant care could address CNI-related endocrine toxicities, but prospective studies are needed to assess the impact on graft and patient survival.
9 citations
,
February 2011 in “Biologics: Targets & Therapy” This review discusses topical calcineurin inhibitors for cutaneous lupus erythematosus and reports no new clinical findings; the authors emphasize the need for more comparative studies with corticosteroids.
1 citations
,
November 2023 in “International Journal of Dermatology” This commentary discusses whether topical steroids or topical calcineurin inhibitors are better for treating scalp atrophy caused by steroid use in patients with scarring alopecia, but specific results or conclusions are not provided.
August 2019 in “International journal of dermatology and venereology” This review discusses the calcineurin/NFAT pathway's role in cutaneous squamous cell carcinoma, noting its involvement in tumor development, skin cell behavior, and the tumor microenvironment; it reports no new results.